Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
April 08 2022 - 1:00PM
Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an
extensive pipeline of therapeutics designed to activate immune
response to cancers and infections, today announced the first
presentation of preclinical data from AGEN1571 – a novel anti-ILT2
antibody designed to modulate tumor-associated macrophages, T, NK
and NKT cells. These data are being presented at the American
Association for Cancer Research (AACR) Annual Meeting being held
April 8-12 in New Orleans, LA.
“The ILT receptor family represents a key suppressor of
anti-tumor immunity that contributes to resistance to CTLA-4 and
PD-1 directed therapies.” said Steven O’Day, MD, Chief Medical
Officer of Agenus. “Blocking this receptor family offers the
potential to overcome this resistance. This approach is validated
by the durable clinical responses achieved in PD-1 resistant
cancers with an ILT4 antagonist discovered by Agenus and licensed
to Merck. AGEN1571 represents our first fully-owned clinical stage
myeloid targeting agent.”
Presentation highlights:
- ILT2 offers a greater potential to
overcome resistance to approved immunotherapies compared to ILT4.
It provides a more prominent and broader expression profile across
immune cell types in the tumor microenvironment.
- AGEN1571 demonstrates superior
functional activity compared to the clinical-stage competitor with:
- ~10-fold higher binding affinity to
all isoforms of ILT2, enabling superior binding to cells expressing
low levels of ILT2
- Complete blockade of ILT2-ligand
interactions for more effective immune activation and anti-tumor
therapeutic potential
- Enhanced activation of T, NK, and
NKT cells for improved tumor-killing
- Superior ability to switch myeloid
cells to a pro-inflammatory state, which further boosts T and NK
cell immunity
- Higher potency in boosting
endogenous anti-tumor immunity to synergize with the patient’s
anti-tumor antibodies or targeted therapies
- Combinations with botensilimab
(Fc-enhanced CTLA-4) and other immuno-oncology agents lead to
stronger immune cell activation
- IND application cleared by the FDA;
clinical trial to commence
Presentation Details:Abstract
Title: AGEN1571 is a novel high-affinity ILT2
antagonist antibody that promotes adaptive and innate immune
responsesAbstract Number: 2906 /
21Session: Therapeutic Antibodies 2Date /
Time: April 12, 2022, 9:00 AM - 12:30 PMPresenting
Author: Olga Udartseva, PhD
The poster presentation can be accessed in the investor section
of the Agenus website
at https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, adoptive cell therapies (through its
subsidiary MiNK Therapeutics), adjuvants, and proprietary cancer
vaccine platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support clinical programs. Agenus is
headquartered in Lexington, MA. For more information, please visit
www.agenusbio.com and our Twitter handle @agenus_bio. Information
that may be important to investors will be routinely posted on our
website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to the use of therapeutic candidate AGEN1571,
for instance, statements regarding therapeutic benefit and
efficacy, mechanism of action (including validation of mechanism of
action), potency, durability, and safety profile (including the
absence of specific toxicities) of the therapeutic candidates, both
alone and in combination with each other and/or other agents (e.g.,
botensilimab in combination with AGEN1571); and any other
statements containing the words "may," "believes," "expects,"
"anticipates," "hopes," "intends," "plans," "forecasts,"
"estimates," "will," “establish,” “potential,” “superiority,” “best
in class,” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
ContactAgenus
Inc.investor@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024